Form 8-K

0001171843-22-003333.txt : 20220506 0001171843-22-003333.hdr.sgml : 20220506 20220505161047 ACCESSION NUMBER: 0001171843-22-003333 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220505 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220505 DATE AS OF CHANGE: 20220505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: STANDARD BIOTOOLS INC. CENTRAL INDEX KEY: 0001162194 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 770513190 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34180 FILM NUMBER: 22896338 BUSINESS ADDRESS: STREET 1: 2 TOWER PLACE STREET 2: SUITE 2000 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6502666000 MAIL ADDRESS: STREET 1: 2 TOWER PLACE STREET 2: SUITE 2000 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: FLUIDIGM CORP DATE OF NAME CHANGE: 20011113 8-K 1 f8k_050522.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 5, 2022

_______________________________

Standard BioTools Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	001-34180	77-0513190
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2 Tower Place, Suite 2000

South San Francisco, California 94080

(Address of Principal Executive Offices) (Zip Code)

(650) 266-6000

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	LAB	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On May 5, 2022, Standard BioTools Inc. issued a press release reporting its financial results for the first fiscal quarter of 2022. A copy of the press release is furnished herewith as Exhibit 99.1.

The foregoing information in this Current Report on Form 8-K, including exhibit 99.1 attached hereto, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such future filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description

99.1		Standard BioTools Inc. Press Release dated May 5, 2022.
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Standard BioTools Inc.


Date: May 5, 2022	By:	/s/ Vikram Jog
		Vikram Jog
		Chief Financial Officer

EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Standard BioTools Announces First Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced financial results for the first quarter ended March 31, 2022.

“The end of first quarter 2022 marked the completion of the company’s strategic evaluation process, which culminated in the closing of a $250 million capital infusion from leading life science investors Casdin Capital, LLC, and Viking Global Investors LP in April 2022,” said Michael Egholm, PhD, Chief Executive Officer and President of Standard BioTools. “While the closing of this transaction marked a major milestone for us and positions us to work hard on improving our base business, our financial performance for the first quarter was, frankly, disappointing and adversely affected by related disruptions in our U.S. sales force, as well as continued COVID-19 related issues, particularly in APAC. We are taking immediate steps to address the operational issues with new leadership including the recent appointment of Jeremy Davis as Chief Commercial Officer. Mindful of our past and its lessons, we now embark on a new chapter of focused execution and growth, and 2022 will serve as the foundation we will build upon.

“During our first few weeks, the new management team has met with numerous key stakeholders, including customers, employees, and partners, and we are highly encouraged and excited by the opportunity before us,” continued Egholm. “Each of these stakeholders sees the opportunity for the now better-capitalized company to better meet the needs of our customers through essential, standardized tools that help them develop breakthrough medicines faster and better.”

Continued Egholm, “Going forward, we will refine our business strategy to build, maintain and strengthen our competitive positions in the markets in which we operate. We will do this by focusing on three areas: First, we will prioritize revenue growth by focusing our efforts to compete in growing market segments where we believe we have or could have a competitive advantage. Specifically, we will focus on servicing more customers in translational and clinical research. Second, we will significantly improve our operating discipline by implementing best-in-class process improvements to manage expenses and increase productivity. Finally, we intend to expand our product offerings for our customers with strategic capital allocation to acquire complementary assets that allow us to leverage our existing infrastructure.

“I believe we now have the resources needed to execute this strategy. I look forward to leading this outstanding team as we embark on this transformation journey and am confident our tool set will indeed accelerate breakthroughs in human health.”

First Quarter 2022 Financial Results

Total revenue was $26.5 million for the quarter ended March 31, 2022, compared with $32.8 million for the first quarter of 2021. The year-over-year decline was primarily driven by lower COVID-19 revenue. Base product and service revenue (excluding COVID-19 testing revenue) was $23.9 million, approximately 2% lower compared with $24.5 million in first quarter 2021.

GAAP net loss for the quarter was $76.3 million, compared with a GAAP net loss of $18.8 million for the first quarter of 2021. The year-over-year increase in GAAP net loss was driven by loss on forward sale of Series B Preferred Stock and change in fair value of bridge loans.

Non-GAAP net loss, which excludes the accounting adjustments for the Series B Preferred Stock and bridge loans, was $19.5 million for the quarter, compared with a non-GAAP net loss of $11.1 million for the first quarter of 2021.

Cash and cash equivalents and restricted cash as of March 31, 2022, was $31.0 million, compared with $29.5 million as of December 31, 2021. Following the completion of the strategic cash infusion by Casdin Capital and Viking Global on April 4, 2022, our cash and cash equivalents and restricted cash was $256.2 million before transaction costs.

Additional Detail on First Quarter 2022 Financial Results

Mass cytometry product and service revenue of $13.5 million for the quarter was down 4 percent over first quarter 2021 driven by lower instrument sales. The launch of our new CyTOF® XT instrument was more than offset by lower sales of our legacy Hyperion™ Imaging System and Helios™ instrument. Going forward, we are seeing encouraging adoption of CyTOF XT™ in the Pharma, Biotech, and CRO segments. Moreover, we expect the recent launch of the Hyperion+™ Imaging System to improve our competitive position in the growing high-plex imaging market.
Base microfluidics product and service revenue, which excludes COVID-19 testing revenue, was $10.4 million, unchanged year-over-year. COVID-19 testing revenue was $2.3 million, down 65% compared with first quarter 2021. Focusing on our base business, we are encouraged by the early adoption of our new Biomark™ X instrument, and our Olink® OEM partnership remains an important growth driver, offsetting weakness in our mature platforms.
Service revenue of $6.1 million was 2% lower year-over-year, following the strong performance for service revenue in fourth quarter 2021.

Revenue by geographic area:

Americas revenue was $12.9 million, down 30% year-over-year, driven almost entirely by lower COVID testing revenue, NRE and grant revenues. The base business in Americas was unchanged year over year.
EMEA revenue was at $8.6 million, down 6% year-over-year. Changes in foreign exchange rates reduced the year-over-year growth by approximately 4 percentage points. COVID-19 continues to negatively impact our business, particularly with new waves in March, as many labs are operating below capacity. Negative impact from the conflict in Ukraine on the European economy together with COVID-19 related expenses on public healthcare systems remain operating headwinds for growth.
Asia-Pacific revenue decreased 3% to $5.0 million. The year-over-year decline was driven by continued COVID-19 related disruptions, particularly in China and Japan.

Recent Highlights

Innovation:

Launched the Hyperion+ Imaging System, the new standard in spatial imaging with superior phenotyping, up to 10x cost savings compared with immunohistochemistry, and the most proven high-plex proteomics approach for scanning eight to 40-plus targets in a single run with easy scaling to 100-plus targets.
Sold 7 CyTOF XT systems in Q1 2022 for a total of 29 since launch.
Sold 9 of our recently launched Biomark X instruments, which shipped in Q1 2022.

Partnerships:

Shipped 18 Olink Signature Q100 benchtop instrument systems, designed and manufactured by Standard BioTools, in Q1 2022.
On February 17, 2022, we announced a collaboration agreement with the Abu Dhabi Stem Cells Center (ADSCC) for development of targeted stem cell therapies and research applications utilizing two Standard BioTools mass cytometry and tissue imaging technologies: Imaging Mass Cytometry™ (IMC™) and the Maxpar® Direct™ Immune Profiling Assay™.

Beachheads:

At quarter end, 200 clinical trials were underway using CyTOF technology.
Total publications and preprints involving CyTOF technology exceeded 2,000, including over 200 publications and preprints for Imaging Mass Cytometry, as of the end of Q1 2022.

Conference Call Information

The Company’s management will host a conference call and webcast today at 2:00 p.m. PT, 5:00 p.m. ET, to discuss first quarter 2022 financial results and operational progress.

Individuals interested in listening to the conference call may do so by dialing:

US domestic callers: (877) 344-8082
Outside US callers: (213) 992-4618

Live audio of the webcast will be available online from the Investor Relations page of the Company’s website at Events & Presentations. The webcast will be archived on Standard BioTools Investor Relations page at investors.fluidigm.com and will be available until May 12.

Due to the appointment in April of new management team members who are focused on completing a 90-day assessment following the closing of a $250 million strategic capital infusion, the company will not be hosting a Q&A session following the conference call.

A reconciliation of GAAP to non-GAAP financial measures can be found in the tables of this release.

Our investor presentation including Supplemental Financial Information has been posted on our website concurrent with this release.

Statement Regarding Use of Non-GAAP Financial Information

Standard BioTools has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three-month periods ended March 31, 2022, and March 31, 2021. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. The time and amount of certain material items needed to estimate non-GAAP financial measures are inherently unpredictable or outside of our control. Material changes to any of these items could have a significant effect on guidance and future GAAP results. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Standard BioTools encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.

Use of Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding operational and strategic plans, revenue growth and business transformation expectations, potential acquisitions, customer adoption of and demand for new products, improvements in competitive position based on introductions of new products, plans with respect to third party relationships and the positive impact of such relationships on growth, and demand trends, including the anticipated impact of geopolitical dynamics and the COVID pandemic. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to the potential adverse effects of the coronavirus pandemic on our business and operating results; possible transition-related disruption, including through the loss of customers, suppliers and employees; changes in Standard BioTools’ business or external market conditions; customers and prospective customers continuing to curtail or suspend activities utilizing our products; our ability and/or the ability of the research institutions utilizing our products and technology to obtain and maintain Emergency Use Authorization from the FDA and any other requisite authorizations or approvals to use our products and technology for diagnostic testing purposes; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, Standard BioTools products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; Standard BioTools research and development and distribution plans and capabilities; interruptions or delays in the supply of components or materials for, or manufacturing of, Standard BioTools products; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Standard BioTools’ business and operating results is contained in its Annual Report on Form 10-K for the year ended December 31, 2021, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Standard BioTools disclaims any obligation to update these forward-looking statements except as may be required by law.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at www.standardbiotools.com or connect with us on Twitter^®, Facebook^®, LinkedIn, and YouTube^™. Standard BioTools, the Standard BioTools logo, Fluidigm, and the Fluidigm logo are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Available Information

Standard BioTools uses its website (standardbiotools.com), investor site (investors.standardbiotools.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about its products, its planned financial and other announcements, its attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and Standard BioTools may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Standard BioTools’ website and its social media accounts in addition to following its press releases, SEC filings, public conference calls, and webcasts.

Investors:
Peter DeNardo
415 389 6400
ir@fluidigm.com

STANDARD BIOTOOLS INC.
(formerly known as FLUIDIGM CORPORATION)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
*(In thousands, except per share amounts)*
(Unaudited)

	Three Months Ended March 31,
		2022			2021
Revenue:
Product revenue	$	20,004		$	24,728
Service revenue		6,144			6,286
Product and service revenue		26,148			31,014
Other revenue (1)		356			1,780
Total revenue		26,504			32,794
Costs and expenses:
Cost of product revenue		12,339			11,663
Cost of service revenue		1,928			2,090
Cost of product and service revenue		14,267			13,753
Research and development		8,865			10,753
Selling, general and administrative		30,875			27,608
Total costs and expenses		54,007			52,114
Loss from operations		(27,503	)		(19,320	)
Interest expense		(1,030	)		(887	)
Loss on forward sale of Series B Preferred Stock		(37,792	)		—
Unrealized loss on bridge loans		(10,655	)		—
Other expense, net		118			(285	)
Loss before income taxes		(76,862	)		(20,492	)
Income tax benefit		574			1,671
Net loss	$	(76,288	)	$	(18,821	)

Net loss per share, basic and diluted	$	(0.99	)	$	(0.25	)
Shares used to compute net loss per share, basic and diluted		77,031			74,707

Note: (1) Other revenue includes product development, license, and grant revenue.

STANDARD BIOTOOLS INC.
(formerly known as FLUIDIGM CORPORATION)
CONDENSED CONSOLIDATED BALANCE SHEETS
*(In thousands)*
(Unaudited)

	March 31, 2022		December 31, 2021 (1)
ASSETS
Current assets:
Cash and cash equivalents (2)	$	29,983	$	28,451
Accounts receivable, net		15,422		18,320
Inventories, net		23,245		20,825
Prepaid expenses and other current assets (2)		4,547		4,470
Total current assets		73,197		72,066
Property and equipment, net		27,699		28,034
Operating lease right-of-use assets, net		36,389		37,119
Other non-current assets (2)		3,445		3,689
Developed technology, net		24,875		27,927
Goodwill		106,333		106,379
Total assets	$	271,938	$	275,214

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	12,517	$	10,602
Accrued compensation and related benefits		7,964		4,920
Operating lease liabilities, current		3,209		3,053
Deferred revenue, current		12,291		11,947
Deferred grant income, current		3,603		3,535
Other accrued liabilities		7,589		8,673
Advances under revolving credit agreement, current		—		6,838
Total current liabilities		47,173		49,568
Bridge loans		35,655		—
Convertible notes, net		54,271		54,160
Term loan, net		10,106		10,049
Deferred tax liability		3,544		4,329
Operating lease liabilities, non-current		36,760		37,548
Deferred revenue, non-current		5,793		5,966
Deferred grant income, non-current		17,237		18,116
Obligation for Series B Preferred Stock		37,792		—
Other non-current liabilities		1,494		882
Total liabilities		249,825		180,618
Total stockholders' equity		22,113		94,596
Total liabilities and stockholders' equity	$	271,938	$	275,214

Notes:
(1) Derived from audited consolidated financial statements
(2) Cash, cash equivalents and restricted cash consist of:
Cash and cash equivalents	$	29,983	$	28,451
Restricted cash (included in other current assets, and other non-current assets)		1,016		1,016
Total cash, cash equivalents and restricted cash	$	30,999	$	29,467

STANDARD BIOTOOLS INC.
(formerly known as FLUIDIGM CORPORATION)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
*(In thousands)*
(Unaudited)

	Three Months Ended March 31,
		2022			2021
OPERATING ACTIVITIES
Net loss	$	(76,288	)	$	(18,821	)
Loss on forward sale of Series B Preferred Stock		37,792			—
Unrealized loss on bridge loans		10,655			—
Stock-based compensation expense		4,042			3,677
Amortization of developed technology		2,968			2,983
Depreciation and amortization		1,003			934
Other non-cash items		1,166			610
Changes in assets and liabilities, net		3,072			(2,284	)
Net cash used in operating activities		(15,590	)		(12,901	)

INVESTING ACTIVITIES
Proceeds from NIH Contract		—			2,000
Purchases of property and equipment		(868	)		(6,923	)
Net cash used in investing activities		(868	)		(4,923	)

FINANCING ACTIVITIES
Proceeds from bridge loans		25,000			—
Repayment of advances under credit agreement		(6,838	)		—
Repayment of long-term debt		—			(501	)
Payments for employee equity programs, net		(87	)		(525	)
Net cash provided by (used in) financing activities		18,075			(1,026	)

Effect of foreign exchange rate fluctuations on cash and cash equivalents		(85	)		74
Net increase (decrease) in cash, cash equivalents and restricted cash		1,532			(18,776	)
Cash, cash equivalents and restricted cash at beginning of period		29,467			69,536
Cash, cash equivalents and restricted cash at end of period	$	30,999		$	50,760

Cash, cash equivalents and restricted cash consist of:
Cash and cash equivalents	$	29,983		$	49,744
Restricted cash (included in prepaid and other current assets, and other non-current assets)		1,016			1,016
Total cash, cash equivalents and restricted cash	$	30,999		$	50,760

STANDARD BIOTOOLS INC.
(formerly known as FLUIDIGM CORPORATION)
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
*(In thousands, except per share amounts)*
(Unaudited)

ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP NET LOSS

	Three Months Ended March 31,
		2022			2021

Net loss (GAAP)	$	(76,288	)	$	(18,821	)
Loss on forward sale of Series B Preferred Stock		37,792			—
Unrealized loss on bridge loans		10,655			—
Stock-based compensation expense		4,042			3,677
Amortization of developed technology (a)		2,967			2,983
Depreciation and amortization		1,003			934
Interest expense (b)		1,030			887
Loss on disposal of property and equipment		9			—
Loss on extinguishment of debt		—			9
Benefit from acquisition related income taxes (c)		(742	)		(742	)
Net loss (Non-GAAP)	$	(19,532	)	$	(11,073	)
Shares used in net loss per share calculation -
basic and diluted (GAAP and Non-GAAP)		77,031			74,707

Net loss per share - basic and diluted (GAAP)	$	(0.99	)	$	(0.25	)
Net loss per share - basic and diluted (Non-GAAP)	$	(0.25	)	$	(0.15	)


ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP PRODUCT AND SERVICE MARGIN

	Three Months Ended March 31,
		2022			2021
Product and service gross profit (GAAP)	$	11,881		$	17,261
Amortization of developed technology (a)		2,967			2,800
Depreciation and amortization (d)		315			420
Stock-based compensation expense (d)		141			98
Product and service gross profit (Non-GAAP)	$	15,304		$	20,579

Product and service margin percentage (GAAP)		45.4	%		55.7	%
Product and service margin percentage (Non-GAAP)		58.5	%		66.4	%












ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP OPERATING EXPENSES

	Three Months Ended March 31,
		2022			2021
Operating expenses (GAAP)	$	39,740		$	38,361
Stock-based compensation expense (e)		(3,901	)		(3,579	)
Depreciation and amortization (e)		(688	)		(697	)
Loss on disposal of property and equipment (e)		(9	)		—
Operating expenses (Non-GAAP)	$	35,142		$	34,085

ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP LOSS FROM OPERATIONS

	Three Months Ended March 31,
		2022			2021
Loss from operations (GAAP)	$	(27,503	)	$	(19,320	)
Stock-based compensation expense		4,042			3,677
Amortization of developed technology (a)		2,967			2,983
Depreciation and amortization (e)		1,003			934
Loss on disposal of property and equipment (e)		9			—
Loss from operations (Non-GAAP)	$	(19,482	)	$	(11,726	)


(a) Represents amortization of developed technology in connection with the DVS and InstruNor acquisitions
(b) Represents interest expense, primarily on convertible debt and the term loan
(c) Represents the tax impact on the purchase of intangible assets in connection with the DVS acquisition
(d) Represents expense associated with cost of product revenue
(e) Represents expense associated with research and development, and selling, general and administrative activities

EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	May 05, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	May 05, 2022
Entity File Number	001-34180
Entity Registrant Name	Standard BioTools Inc.
Entity Central Index Key	0001162194
Entity Tax Identification Number	77-0513190
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2 Tower Place, Suite 2000
Entity Address, City or Town	South San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94080
City Area Code	650
Local Phone Number	266-6000
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	LAB
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 8 f8k_050522_htm.xml IDEA: XBRL DOCUMENT 0001162194 2022-05-05 2022-05-05 iso4217:USD shares iso4217:USD shares 0001162194 false 8-K 2022-05-05 Standard BioTools Inc. DE 001-34180 77-0513190 2 Tower Place, Suite 2000 South San Francisco CA 94080 650 266-6000 false false false false Common Stock, $0.001 par value per share LAB NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_050522.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_050522.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "inline": { "local": [ "f8k_050522.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_050522.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_050522.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001171843-22-003333-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-22-003333-xbrl.zip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